Stromal Disrupting Effects of Nab-paclitaxel in Pancreatic Cancer

Overview

Journal Br J Cancer

Specialty Oncology

Date 2013 Aug 3

PMID 23907428

Citations 147

Authors

R Alvarez

M Musteanu

E Garcia-Garcia

P P Lopez-Casas

D Megias

C Guerra

M Munoz

Y Quijano

A Cubillo

J Rodriguez-Pascual

C Plaza

E de Vicente

S Prados

S Tabernero

M Barbacid

F Lopez-Rios

M Hidalgo

Affiliations

Soon will be listed here.

Abstract

Background: Nab-paclitaxel and gemcitabine have demonstrated a survival benefit over gemcitabine alone in advanced pancreatic cancer (PDA). This study aimed to investigate the clinical, biological, and imaging effects of the regimen in patients with operable PDA.

Methods: Patients with operable PDA received two cycles of nab-paclitaxel and gemcitabine before surgical resection. FDG-PET and CA19.9 tumour marker levels were used to measure clinical activity. Effects on tumour stroma were determined by endoscopic ultrasound (EUS) elastography. The collagen content and architecture as well as density of cancer-associated fibroblasts (CAFs) were determined in the resected surgical specimen and compared with a group of untreated and treated with conventional chemoradiation therapy controls. A co-clinical study in a mouse model of PDA was conducted to differentiate between the effects of nab-paclitaxel and gemcitabine.

Results: A total of 16 patients were enrolled. Treatment resulted in significant antitumour effects with 50% of patients achieving a >75% decrease in circulating CA19.9 tumour marker and a response by FDG-PET. There was also a significant decrement in tumour stiffness as measured by EUS elastography. Seven of 12 patients who completed treatment and were operated had major pathological regressions. Analysis of residual tumours showed a marked disorganised collagen with a very low density of CAF, which was not observed in the untreated or conventionally treated control groups. The preclinical co-clinical study showed that these effects were specific of nab-paclitaxel and not gemcitabine.

Conclusion: These data suggest that nab-paclitaxel and gemcitabine decreases CAF content inducing a marked alteration in cancer stroma that results in tumour softening. This regimen should be studied in patients with operable PDA.

Citing Articles

Dual-energy CT extracellular volume fraction predicts tumor collagen ratio and possibly survival for inoperable pancreatic cancer patients.

Liu W, Chen Y, Xie T, Zhang Z, Wang Y, Xie X Eur Radiol. 2025; 35(3):1451-1463.

PMID: 39922972 DOI: 10.1007/s00330-024-11330-1.

Probing the physical hallmarks of cancer.

Nia H, Munn L, Jain R Nat Methods. 2025; .

PMID: 39815103 DOI: 10.1038/s41592-024-02564-4.

Combinational CAR T-cell therapy for solid tumors: Requisites, rationales, and trials.

Misawa K, Bhat H, Adusumilli P, Hou Z Pharmacol Ther. 2024; 266:108763.

PMID: 39617146 PMC: 11848936. DOI: 10.1016/j.pharmthera.2024.108763.

Lymphodepletion in Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors: A Focus on Brain Tumors.

Ju A, Choi S, Jeon Y, Kim K Brain Tumor Res Treat. 2024; 12(4):208-220.

PMID: 39542517 PMC: 11570086. DOI: 10.14791/btrt.2024.0037.

Development and validation of a CT-based radiomics model to predict survival-graded fibrosis in pancreatic ductal adenocarcinoma.

Shi S, Liu R, Zhou J, Liu J, Lin H, Mo J Int J Surg. 2024; 111(1):950-961.

PMID: 39172712 PMC: 11745594. DOI: 10.1097/JS9.0000000000002059.

References

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

Von Hoff D, Ramanathan R, Borad M, Laheru D, Smith L, Wood T . Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol. 2011; 29(34):4548-54. PMC: 3565012. DOI: 10.1200/JCO.2011.36.5742. View

Andriulli A, Festa V, Botteri E, Valvano M, Koch M, Bassi C . Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies. Ann Surg Oncol. 2011; 19(5):1644-62. DOI: 10.1245/s10434-011-2110-8. View

Infante J, Matsubayashi H, Sato N, Tonascia J, Klein A, Riall T . Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol. 2007; 25(3):319-25. DOI: 10.1200/JCO.2006.07.8824. View

Chun Y, Cooper H, Cohen S, Konski A, Burtness B, Denlinger C . Significance of pathologic response to preoperative therapy in pancreatic cancer. Ann Surg Oncol. 2011; 18(13):3601-7. DOI: 10.1245/s10434-011-2086-4. View

Janssen J, Schlorer E, Greiner L . EUS elastography of the pancreas: feasibility and pattern description of the normal pancreas, chronic pancreatitis, and focal pancreatic lesions. Gastrointest Endosc. 2007; 65(7):971-8. DOI: 10.1016/j.gie.2006.12.057. View

Frese K, Neesse A, Cook N, Bapiro T, Lolkema M, Jodrell D . nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discov. 2012; 2(3):260-269. PMC: 4866937. DOI: 10.1158/2159-8290.CD-11-0242. View

Erkan M, Michalski C, Rieder S, Reiser-Erkan C, Abiatari I, Kolb A . The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma. Clin Gastroenterol Hepatol. 2008; 6(10):1155-61. DOI: 10.1016/j.cgh.2008.05.006. View

Provenzano P, Cuevas C, Chang A, Goel V, Von Hoff D, Hingorani S . Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell. 2012; 21(3):418-29. PMC: 3371414. DOI: 10.1016/j.ccr.2012.01.007. View

10.

Guerra C, Collado M, Navas C, Schuhmacher A, Hernandez-Porras I, Canamero M . Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence. Cancer Cell. 2011; 19(6):728-39. PMC: 4890723. DOI: 10.1016/j.ccr.2011.05.011. View

11.

Arnold S, Rivera L, Miller A, Carbon J, Dineen S, Xie Y . Lack of host SPARC enhances vascular function and tumor spread in an orthotopic murine model of pancreatic carcinoma. Dis Model Mech. 2009; 3(1-2):57-72. PMC: 2806901. DOI: 10.1242/dmm.003228. View

12.

Mahadevan D, Von Hoff D . Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther. 2007; 6(4):1186-97. DOI: 10.1158/1535-7163.MCT-06-0686. View

13.

Hidalgo M . Pancreatic cancer. N Engl J Med. 2010; 362(17):1605-17. DOI: 10.1056/NEJMra0901557. View

14.

Dawwas M, Taha H, Leeds J, Nayar M, Oppong K . Diagnostic accuracy of quantitative EUS elastography for discriminating malignant from benign solid pancreatic masses: a prospective, single-center study. Gastrointest Endosc. 2012; 76(5):953-61. DOI: 10.1016/j.gie.2012.05.034. View

15.

Ryan R, Gibbons D, Hyland J, Treanor D, White A, Mulcahy H . Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology. 2005; 47(2):141-6. DOI: 10.1111/j.1365-2559.2005.02176.x. View

16.

Olive K, Jacobetz M, Davidson C, Gopinathan A, McIntyre D, Honess D . Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009; 324(5933):1457-61. PMC: 2998180. DOI: 10.1126/science.1171362. View

17.

Von Hoff D, Korn R, Mousses S . Pancreatic cancer--could it be that simple? A different context of vulnerability. Cancer Cell. 2009; 16(1):7-8. DOI: 10.1016/j.ccr.2009.06.011. View

18.

Jacobetz M, Chan D, Neesse A, Bapiro T, Cook N, Frese K . Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut. 2012; 62(1):112-20. PMC: 3551211. DOI: 10.1136/gutjnl-2012-302529. View

19.

Iglesias-Garcia J, Larino-Noia J, Abdulkader I, Forteza J, Dominguez-Munoz J . Quantitative endoscopic ultrasound elastography: an accurate method for the differentiation of solid pancreatic masses. Gastroenterology. 2010; 139(4):1172-80. DOI: 10.1053/j.gastro.2010.06.059. View